Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tool aims to cut chemo toxicity for seniors with cancer

NCT ID NCT06870617

Symptom relief Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tests a practical geriatric assessment (PGA) for adults aged 70+ with advanced cancer. The PGA is a questionnaire completed before a doctor visit, and results are shared with the care team to help guide chemotherapy dosing. Researchers will also track step counts with a FitBit and measure body composition from CT scans to see if these factors relate to side effects. The goal is to make geriatric assessments easier to use and reduce treatment-related toxicity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Practical Geriatric Assessment (PGA) questionnaire and FitBit step monitoring
What this could lead to
If successful, this could make geriatric assessments easier to use in clinics, helping doctors tailor chemotherapy to reduce side effects in older patients.
What could go wrong
This is an early implementation study, not a large trial. The assessment may not change outcomes, and results may not apply to all older cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible participants will be 70 years or older, have a diagnosis of advanced or metastatic solid malignancy, and be starting a new line of palliative-intent systemic therapy, where the expected prevalence of grade 3 toxicity exceeds 50 percent.

Ages

70 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For PGA Implementation Cohort, patients must meet the following criteria: 1. Age greater than or equal to 70 years. 2. Diagnosis of advanced or metastatic solid malignancy 3. Initiating a new line of palliative-intent systemic therapy with a prevalence of grade 3 toxicity exceeding 50%. For Correlative Analysis Cohort, patients must additionally meet the following criteria: 1. Must read and speak English and be able to fill out surveys 2. Ability to walk independently or with the use of an assistive device (e.g., walker, cane) 3. Consents to participate in correlative analysis cohort with Fitbit monitoring, body composition analysis, and self-report surveys 4. Have a smartphone able to operate with the Fitbit For PGA Implementation Cohort, there are no specific exclusion criteria other than not meeting inclusion criteria. For Correlative Analysis Cohort, patients will be excluded if meeting any of the following criteria: 1. Unable to effectively read and speak English 2. Reliance on a wheelchair, ECOG of 3 or above, clinically bedbound, or unable to walk without assistance every day for the past 7 days (ECOG 3 is confined to bed or chair for more than 50% of waking hours) 3. Concurrent enrollment in a therapeutic clinical trial (as clinical trials often have a substantial symptom-reporting structure). Non-therapeutic clinical trial enrollment is permitted 4. Lack of clinician consent to approach patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced cancer Geriatric assessment Toxicity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lancaster General Hospital

    NOT_YET_RECRUITING

    Lancaster, Pennsylvania, 17602, United States

  • Penn Medicine Princeton Medical Center

    RECRUITING

    Princeton, New Jersey, 08540, United States

  • Pennsylvania Hospital

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.